Adjuvant capecitabine in combination with docetaxel and cyclophosphamide versus anthracycline plus docetaxel and cyclophosphamide regimen in women with high-risk, HER2-negative breast cancer: An open-label, randomized controlled trial.

Cancer Commun (Lond) · 2025 · PMC12479128 · PMID 40491042

Europe PMC DOI

hedged sentences

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

did not reach statistical significanceP = 0.052so close (0.05 < p ≤ 0.1)

Compared to the TAC group, a trend favoring the TCX group was also observed in DDFS, although this difference did not reach statistical significance ( P = 0.052; Figure 2B ).

also in 111,027 other papers

borderline significantno p-value reported

Although the difference in DFS between the two groups did not reach statistical significance, TCX exhibited a borderline significant advantage in DDFS, highlighting its potential for reducing distant recurrences.

also in 11,409 other papers

borderline significanceno p-value reported

More importantly, DDFS, which is more closely related to recurrence and mortality, demonstrated borderline significance, with fewer distant metastases observed in the TCX group.

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.